Synthesis and modification of uniform PEG-neridronate-modified magnetic nanoparticles determines prolonged blood circulation and biodistribution in a mouse preclinical model

Vitalii Patsula1, Daniel Horák1, Jan Kučka1, Hana Macková1, Volodymyr Lobaz1, Pavla Francová2, Vit Herynek2, Tomáš Heizer2, Petr Páral2 & Luděk Šefc2

Magnetite (Fe3O4) nanoparticles with uniform sizes of 10, 20, and 31 nm were prepared by thermal decomposition of Fe(III) oleate or mandelate in a high-boiling point solvent (>320 °C). To render the particles with hydrophilic and antifouling properties, their surface was coated with a PEG-containing bisphosphonate anchoring group. The PEGylated particles were characterized by a range of physicochemical methods, including dynamic light scattering, transmission electron microscopy, thermogravimetric analysis, Fourier transform infrared spectroscopy, and magnetization measurements. As the particle size increased from 10 to 31 nm, the amount of PEG coating decreased from 28.5 to 9 wt.%. The PEG formed a dense brush-like shell on the particle surface, which prevented particles from aggregating in water and PBS (pH 7.4) and maximized the circulation time in vivo. Magnetic resonance relaxometry confirmed that the PEG-modified Fe3O4 nanoparticles had high relaxivity, which increased with increasing particle size. In the in vivo experiments in a mouse model, the particles provided visible contrast enhancement in the magnetic resonance images. Almost 70% of administrated 20-nm magnetic nanoparticles still circulated in the blood stream after four hours; however, their retention in the tumor was rather low, which was likely due to the antifouling properties of PEG.

The previous several decades of continuous research in the field of nanotechnology has resulted in the development of a variety of nanomaterials with specially tailored properties, allowing their application in biomedicine1-2. Among them, magnetic nanoparticles are distinct due to their unique magnetic properties, large surface-to-volume ratio, small size, and ability to function at the cellular level. These characteristics make them appropriate candidates for medical applications, such as contrast agents for magnetic resonance imaging (MRI), magnetically guided carriers for drug delivery, or heat mediators for hyperthermia3-5. Magnetic nanomaterials, which incorporate metallic, bimetallic, and metal oxide nanoparticles6, in particular, maghemite (γ-Fe2O3) and magnetite (Fe3O4), are advantageous due to their low toxicity7, biocompatibility and the possibility of easily modifying the surface with polymer shells, drugs and/or targeting and imaging ligands8,9. In organism, intravenously administrated iron oxide nanoparticles are recognized by mononuclear phagocytic system depending on the size and transported to organs, predominantly liver and spleen (d > 8 nm), or filtered via kidneys (d < 8 nm)10. Borderline in size excluded by kidneys is not sharp; even 10 or 14 nm particles were found in urine11,12. At the cellular level, mainly liver sinusoidal endothelial cells, Kupffer cells, and splenic red pulp macrophages gradually
degrade iron oxides in the lysosomes\textsuperscript{13}, subsequently transferring Fe to endogenous iron storing proteins\textsuperscript{14}. After intravascular administration, particles should be collooidally stable at a high ionic strength, which can induce particle agglomeration and trigger recognition and clearance by the reticuloendothelial system. Consequently, physicochemical properties, i.e., size, polydispersity, geometry, charge, and surface coating are critical parameters strongly determining ability of the particles to circulate in the blood stream. These characteristics can be controlled by the selection of a proper method for nanoparticle preparation. Currently, many approaches for iron oxide synthesis have been developed to improve the control of particle morphology and surface properties. These methods include coprecipitation, microemulsion, sol-gel, flame spray pyrolysis, thermal decomposition, etc.\textsuperscript{15–17}. The latter technique has a significant advantage because it allows the preparation of uniform particles with excellent control over their size and magnetism. A defined particle size, together with uniformity, can provide more precise and reproducible in vivo results than particles with a broad size distribution\textsuperscript{12}. However, the significant disadvantage of this method is the hydrophobic nature of the particle coating, which requires additional postsynthetic modifications, e.g., ligand exchange to make the particles water-dispersible and applicable in biomedicine.

Earlier publications described superior results obtained with poly(ethylene glycol) (PEG)-based coating of iron oxides attributed to its hydrophilicity, biocompatibility, non-antigenicity, and anti fouling properties, which remarkably extend circulation of nanoparticles in blood\textsuperscript{12}. However, the behavior of PEGylated particles strongly depends on the molecular weight ($M_w$) of PEG and its architecture and surface density that affect the chain conformation at the surface\textsuperscript{18,19}. Generally, stealth properties of nanoparticles in the blood stream are achieved by highly dense PEG shells with $M_w = 2–10$ kg/mol\textsuperscript{19}. The conjugation of macromolecules to particle surfaces can be achieved by anchoring groups capable of strong interactions with iron, e.g., aromatic vicinal diols, carboxyls, bisphosphonates, or hydroxamates\textsuperscript{20–22}; the strongest bonding is achieved with bisphosphonate groups\textsuperscript{23,24}. In particular, polymers containing hydroxybisphosphonate anchoring groups provide magnetite or lanthanide nanoparticle dispersions that are colloidal stable under physiological conditions\textsuperscript{20–22}. Such polymers are exemplified by PEG with hydroxybisphosphonate terminal moieties prepared via EDC/NHS chemistry or chloranhydrate\textsuperscript{29}. PEGylated iron oxide particles also increase the blood circulation time. For example, poly(maleic anhydride-alt-1-octadecene)-PEG-coated iron oxide provided blood half-life 105 min in mice\textsuperscript{30}. PEGylated-arginin-coated iron oxide had at least 2 h circulation time\textsuperscript{31}, and also (3-aminopropyl)triethoxysilane-PEG-functionalized or dopamine-PEG-coated magnetite escaped from the uptake by reticular endothelial system\textsuperscript{32,33}.

The aim of this work was to prolong the circulation of iron oxide nanoparticles in the blood stream by optimizing their physiochemical parameters, compare them with literature\textsuperscript{27,30,34} and utilize the particles for passive tumor targeting via the enhanced permeability and retention (EPR) effect in a mouse model. We assume that this behavior will be beneficial especially for drug delivery systems, where drug can be released from the particles by changing pH. Differently sized magnetic nanoparticles were synthesized by a thermal decomposition method. To achieve superior colloidal stability of the particles in aqueous media, their surface was modified with PEG terminated by bisphosphonate anchoring groups (neridronate). The nanoparticles were characterized by various physicochemical methods to analyze the size, relaxivity, magnetization, and PEG surface density, and blood circulation time was determined in a mouse model. The particle accumulation in the tumor via EPR effect was also investigated.

**Experimental Materials.** Octa dec-1-ene (OD, 99%), isoothane (IS, 99%), and FeCl$_2$·6H$_2$O (98%) were purchased from Sigma-Aldrich (St. Louis, MO, USA). Oleic acid (OA; 95%), hexane (99%), dichloromethane (99.9%), petroleum ether (b.p. 40–60°C) ethanol (99%), NaOH (98.6%), HCl (35%), and salts (Na$_2$HPO$_4$·12-H$_2$O, KH$_2$PO$_4$, and NaCl) used for the preparation of 0.1 M phosphate buffer saline (PBS) were obtained from Lach-Ner (Neratovice, Czech Republic). α-Methoxy poly(ethylene glycol) succinimidyl ester (PEG-NHS; $M_w = 2000$ g/mol) was purchased from Rapp Polymere (Tuebingen, Germany). Cellulose dialysis membrane (14 kg/mol) was obtained from Spectrum Europe (Breda, Netherlands). Bovine serum albumin fraction V (BSA; $M_w = 67$ kg/mol) was purchased from Serva Electrophoresis (Heidelberg, Germany). Isouluarane was obtained from Baxter (San Juan, Puerto Rico). Fe(III) olete and mandelate were prepared according to previous publication\textsuperscript{23}. Additionally, 6-amino-1-hydroxy-1,1-hexanediylbis(phosphonic acid) monosodium salt (neridronate) was prepared according to a previously published report\textsuperscript{35}. Ultrapure Q-water that was ultrafiltered using a Milli-Q Gradient A10 system (Millipore; Molsheim, France) was used in all experiments. All other reagent grade chemicals were purchased from Sigma-Aldrich and used as received.

**Synthesis of Fe$_3$O$_4$ nanoparticles.** Monodisperse 10-nm Fe$_3$O$_4$ nanoparticles were synthesized by the thermal decomposition of Fe(III) oleate at 320°C. Briefly, Fe(III) olete (5.76 g) and OA (4.55 g) were dissolved in OD (40 ml) and the mixture was preheated at 125°C for 60 min, and then heated at 320°C for 30 min. The 20 and 31 nm Fe$_3$O$_4$ particles were obtained by the thermal decomposition of Fe(III) mandelate (3.26 g) in the presence of OA (4.4 g) in OD (40 ml) at 320°C for 30 min or in IS (40 ml) at 343°C for 60 min, respectively. The reaction was cooled to room temperature (RT), and the particles were precipitated by ethanol (100 ml) and magnetically separated. To remove the residual solvents and OA, the particles were washed with hot ethanol five times (~70°C; 50 ml for each wash) and finally redispersed in toluene under Ar and stored.

**Synthesis of PEG-neridronate (PEG-Ner).** Neridronate (1.36 g) was dissolved in 0.5 M phosphate buffer (3 ml; pH 7.3) at 0°C, the pH of the solution was maintained at 7.3 by adding 4 M aqueous NaOH, PEG-NHS (1 g) was added, and the reaction mixture was stirred at 0°C for 6 h and then at RT for 16 h. After the reaction was completed, the pH was adjusted to 6 by adding 4 M HCl, PEG-Ner was extracted with CH$_2$Cl$_2$ (3 × 8 ml), the organic layers were united, and the solution was filtered through a 0.45 μm filter. CH$_2$Cl$_2$ was removed on a rotary evaporator at 30°C, and the solid residue was dissolved in water (5 ml). To retrieve the phosphate groups on
PEG-Ner, the aqueous solution was passed through an ion-exchange column packed with sulfonated polystyrene resin. Water was removed from the solution using a rotary evaporator at 60 °C (2.5 kPa) and PEG-Ner was finally vacuum-dried at 60 °C over phosphorus pentoxide.

**Synthesis of PEG-modified Fe₃O₄ nanoparticles (Fe₃O₄@PEG-Ner).** PEG-Ner (150 mg) was added to Fe₃O₄ nanoparticles (50 mg) in toluene/1,4-dioxane (3:2 v/v; 10 ml), the mixture was sonicated (UP200S Hielser Ultrasonic Technology; Teltow, Germany) for 5 min at 100 W, purged with Ar for 15 min, and stirred (900 rpm) at 70 °C for 48 h. The resulting PEG-modified Fe₃O₄ particles (Fe₃O₄@PEG-Ner) were precipitated three times with petroleum ether (80 ml for each precipitation), separated by a magnet, redispersed in water, and dialyzed against water for 48 h using a cellulose dialysis membrane (14 kg/mol). The final Fe₃O₄@PEG-Ner concentration reached ~4.5 mg/ml.

**Nanoparticle characterization.** Transmission electron microscopy (TEM) micrographs of the particles were obtained with a Tecnai G2 Spirit Twin 12 transmission electron microscope (TEM; FEI; Brno, Czech Republic). The number-average diameter ($D_\text{n} = \Sigma N_i D_i / \Sigma N_i$), weight-average diameter ($D_\text{w} = \Sigma N_i D_i^3 / \Sigma N_i D_i$) and dispersity ($D = D_\text{w}/D_\text{n}$) were determined by the measurement of at least 600 particles from TEM micrographs using Atlas software (Tescan Digital Microscopy Imaging; Brno, Czech Republic); $N_i$ is the number and $D_i$ is the diameter of $i$th particle. The hydrodynamic diameter $D_h$, polydispersity (PI) and electrophoretic mobility of the magnetic nanoparticles, which was converted to $\zeta$-potential using the Smoluchowski equation, were obtained by dynamic light scattering (DLS) using a ZEN 3600 Zetasizer Nano instrument (Malvern Instruments; Malvern, UK) at RT. The $D_h$ was calculated from the intensity-weighted distribution function obtained by CONTIN analysis of the correlation function embedded in Malvern software. The iron oxide content was determined using a PerkinElmer TGA 7 thermogravimetric analyzer (Norwalk, CT, USA). The PEGylated nanoparticles were heated from RT to 800 °C at 10 °C/min in air. ATR FTIR spectra were obtained on a PerkinElmer Paragon 1000PC spectrometer equipped with a Specac MKII Golden Gate single attenuated total reflection (ATR) system with a diamond crystal; the angle of incidence was 45°. Magnetization curves were measured at 300 K by an ADE Magnetics model EV9 VSM magnetometer (MicroSense; Lowell, MA, USA).

The grafting density ($\sigma$) of PEG on the particle surface was calculated according to Eq. (1) as follows:

$$\sigma = \frac{(m_{\text{PEG}}/m_{\text{Fe₃O₄}})\rho_{\text{Fe₃O₄}} V N_A}{M_N S}$$

where $m_{\text{PEG}}$ and $m_{\text{Fe₃O₄}}$ are the weight percentages of PEG and iron oxide in the particles according to TGA, respectively, $\rho$ is the density of magnetite (5.18 kg/m$^3$), $N_A$ is Avogadro's number, and $M_N$ is the number-average molecular weight of PEG-Ner (2,165 g/mol).

The relaxivity ($r_2$) of the magnetic nanoparticles was measured at 5–65 °C using a MiniSpec mq20 relaxometer (Bruker; Rheinstetten, Germany). The particle colloids were diluted to concentrations of 8–11 μg of Fe₃O₄/ml, and the $T_2$ relaxation times were measured using a Carr Purcell Meiboom Gill (CPMG) multi-spin echo sequence (echo spacing $2\tau = 2$ ms, repetition time $TR = 5$ s, and number of acquisitions $NA = 8$). The colloids were vortexed before each measurement. The relaxivity $r_2$ was calculated as a reciprocal value of $T_2$ divided by the nanoparticle concentration (after subtraction of the solvent contribution).

**In vivo biodistribution of Fe₃O₄@PEG-Ner particles in mice.** Animals. C57BL/6NCrl mice were bred in a specific-pathogen free animal facility of the First Faculty of Medicine, Charles University (Prague, Czech Republic), and maintained in individually ventilated cages (12:12 h light-dark cycle, 22 ± 1 °C, 60 ± 5% humidity). The studies used adult male mice (6–8 weeks old) with free access to water and a standard rodent diet. The experiments were performed in accordance with national and international guidelines for laboratory animal care and approved by the Laboratory Animal Care and Use Committee of the First Faculty of Medicine, Charles University, and the Ministry of Education, Youth and Sports of the Czech Republic (MSMT-6316/2014-46).

MRI. The 10, 20, and 31 nm Fe₃O₄@PEG-Ner colloids (50 μl per animal) were intravenously injected into mice through the tail vein (each particle type was administered separately into different mice, and the control mouse was scanned without nanoparticle application). The animals were then subjected to MRI scanning using a 1 T ICON scanner (Bruker BioSpin; Ettlingen, Germany). The scanning protocol consisted of a localizer sequence (a fast gradient echo sequence providing images in three orthogonal slices with low resolution), a $T_2/T_2^*$-weighted gradient echo sequence (echo time $TE = 4$ ms, $TR = 160$ ms, flip angle $FA = 80^\circ$, $NA = 16$), and a strongly $T_2^*$-weighted gradient echo sequence ($TE = 8$ ms, $TR = 400$ ms, $FA = 60^\circ$, $NA = 8$). The same geometry (1 mm coronal slices, 30 × 60 mm field of view, 128 × 256 matrix) was used for both sequences. The mice were anesthetized by spontaneous inhalation of isoflurane (5% for induction and 1.5% for maintenance) for both procedures (particle administration and MR scanning).

Assessment of nanoparticle circulation in blood. The 10, 20, and 31 nm Fe₃O₄@PEG-Ner colloids (50 μl per animal) were intravenously injected into the mice through the tail vein (each particle type was administered separately into three different mice, and two mice without particle administration were used as controls). Blood (100 μl) was obtained from the retro-orbital plexus at 5 and 30 min and 2, 4, 24, and 48 h after Fe₃O₄@PEG-Ner injection. Blood was collected in test tubes with the addition of sodium heparin to prevent coagulation. The $T_2$ relaxation times were measured for each blood sample at 37 °C using a CPMG multi-spin echo sequence ($TE = 2$ ms, $TR = 5$ s, and $NA = 8$). The nanoparticle concentration ($c$) in blood was calculated from the nanoparticle...
relaxivities ($r_2$) after the deduction of a contribution of the pure blood to the relaxation rate according to equation (2) as follows:

$$c = \frac{1}{T_{2bNP}} - \frac{1}{T_{2b}} / r_2$$

where $T_{2bNP}$ and $T_{2b}$ are the relaxation times of the blood sample with nanoparticles and pure blood, respectively.

**MRI of Fe$_3$O$_4$@PEG-Ner nanoparticles in tumor-bearing mice.** EL-4 (ATCC® TIB-39™) mouse lymphoma cells were subcutaneously inoculated into C57Bl/6 mice ($n = 4$). Fe$_3$O$_4$@PEG-Ner-20 nanoparticles were intravenously administered in three doses (50 μl each) as follows: the first dose was administered one week after tumor implantation and the second and third doses were administered in 24 h intervals to prolong the blood circulation time. MRI was performed before nanoparticle administration (0 h time point), then 4 h after each particle administration, i.e., at 4, 28, and 52 h time points, and then at 120 and 192 h. The same MR scanning protocol was used as mentioned above.

**Results and Discussion**

**Control of magnetic nanoparticle size.** Uniformly-sized magnetic nanoparticles were prepared by the thermal decomposition of iron(III) carboxylates in high-boiling point solvents in the presence of OA as a stabilizer, which resulted in magnetite spinel phase, as confirmed by X-ray powder analysis. The particle size was controlled by changing various reaction parameters, such as the type of iron precursor, amount of OA, reaction time and temperature. Decomposition of iron(III) oleate in OD (b.p. 320 °C) for 30 min in the presence of OA (4.55 g) produced 10 nm nanoparticles with $D = 1.05$ (Fig. 1a). The 20 nm ($D = 1.03$) Fe$_3$O$_4$ particles were obtained by decomposition of iron(III) mandelate under similar reaction conditions, but with a slightly lower amount of OA (4.4 g; Fig. 1b). In terms of morphology, the Fe$_3$O$_4$ particles were quite comparable with those reported earlier.

The variation in the particle size can be explained by different decomposition profiles of selected iron precursors. As shown previously, iron(III) mandelate decomposes faster; therefore, the nanoparticles nucleate and grow at lower temperatures than those from iron(III) oleate; as a result, larger particles were obtained. Increasing the reaction temperature to 343 °C and prolonging the reaction time from 30 to 60 min during the decomposition of iron(III) mandelate resulted in the formation of large, 31 nm Fe$_3$O$_4$ particles with a narrow size distribution ($D = 1.05$). This formation could be attributed to an increased growth rate and a prolonged reaction time at an elevated temperature. According to TEM, the nanoparticles were almost spherical in shape (Fig. 1a–c).

**Engineering of the Fe$_3$O$_4$ surface with PEG-Ner.** OA-coated magnetite nanoparticles are hydrophobic, which are not suitable for future biological use. Because the particles were injected in mice in physiological buffers, water-dispersible particles were required; therefore, the hydrophobic coating of the original particles needed to be exchanged with a hydrophilic coating. Iron oxide nanoparticles contain a large number of hydroxyl groups on the surface, which can be used for the covalent attachment of hydrophilic molecules. In this study, iron oxide nanoparticles with different sizes were modified with bis(phosphonic acid)-terminated PEG prepared from PEG-NHS and neridronate, which is in contrast to commonly used alendronate. PEG, which is a biocompatible and highly hydrophilic polyether that provides strong steric repulsions, is frequently used in medicine for the preparation of various pharmaceutical formulations. The advantage of bisphosphonate groups is their strong affinity for metal ions, such as iron. Bisphosphonic acid-terminated PEG can thus be strongly bound to the Fe$_3$O$_4$ nanoparticle surface. Moreover, neridronate is biocompatible and has been approved for clinical use in the treatment of various bone illnesses.

Fe$_3$O$_4$@PEG-Ner particles were thoroughly characterized by a range of physicochemical methods, including DLS, FTIR spectroscopy, thermogravimetric analysis (TGA), and magnetization measurements. The ATR FTIR spectra of all Fe$_3$O$_4$@PEG-Ner particles were compared with that of OA-coated Fe$_3$O$_4$ (Fig. 2a). While the 10-nm OA-coated particles exhibited peaks at 2,920, 2,851, and 1,466 cm$^{-1}$ assigned to the $ν$($CH_3$), $ν$($CH_2$) asymmetric, and $ν$(C=O) stretching vibrations, respectively, originating from OA, the strong band at 1,050 cm$^{-1}$ attributed
to the vibration of the C-O-C group confirmed the presence of PEG on the Fe₃O₄@PEG-Ner surface. Let us note that the ATR FTIR spectra of 20- and 31-nm OA-coated particles resembled that to the 10-nm one (data not shown). According to TGA, the amount of PEG on the nanoparticle surface decreased with increasing particle size, reaching 29, 17, and 9 wt.% for 10, 20, and 31 nm particles, respectively (Table 1, Fig. 2b).

Different amounts of PEG on the particles can be explained by the larger surface-to-volume ratio of the 10 nm particle than those of the 20 and 31 nm particles, resulting in an increased amount of bound PEG on the smallest particles. The highest PEG grafting density was found on the 20 nm particles (1.02 PEG/nm²), while the lowest density was found on the 31 nm particles (0.76 PEG/nm²; Table 1). In theory, if the molecular weight and surface density of PEG are known, it is possible to predict its conformation 18. The grafting density controls the conformation of PEG chains on the surface, which can be brush-like or mushroom-like. Generally, the mushroom-like conformation is observed at low surface density when \( d > r_f \), where \( d \) is the distance between the attachment points of the polymer on the surface and \( r_f \) is the Flory radius. Furthermore, \( d < r_f \) indicates a brush-like conformation 19. The \( r_f \) was 3.44 nm for PEG and \( d \) was 1, 0.99, and 1.15 nm for Fe₃O₄@PEG-Ner-10, -20, and -31, respectively. The fact that \( d \) was smaller than \( r_f \) in all PEGylated nanoparticles confirmed dense packing of PEG on the surface in a brush-like conformation. This organization of the shell is beneficial for the application of magnetic nanoparticles in medicine because it could significantly decrease protein adsorption and recognition by macrophages and prolong particle circulation in the blood stream 19.

The hydrodynamic diameters \( D_h \) of Fe₃O₄@PEG-Ner-10, -20, and -31 were 35, 39, and 62 nm in water and 34, 39, and 62 nm in PBS (pH 7.4), respectively (Table 1). The polydispersity (PI) was 0.2, 0.1, and 0.14 in water and 0.26, 0.16, and 0.11 in PBS for Fe₃O₄@PEG-Ner-10, -20, and -31 nanoparticles, respectively. The difference in \( D_h \) and \( D_P \) (the size of the dried particles obtained by TEM) was attributed to the binding of PEG to the particle surface. Relatively similar \( D_h \) values of the particles in both media confirmed that the particles possessed good colloidal stability. The particle \( \zeta \)-potential ranged from \(-9 \) to \(-15 \) mV and from \(-3 \) to \(-6 \) mV in water and PBS, respectively. A relatively low negative surface charge was likely caused by the presence of phosphonate groups.

Monitoring of the magnetic nanoparticles in both water and PBS for one week showed no significant changes in the \( D_h \) and \( \zeta \)-potential, indicating excellent longtime colloidal stability that is crucial for biomedical applications (Fig. 3a,b). This observation also suggests that the particles were mainly stabilized by strong steric repulsions of PEG chains on the particle surface, which, in contrast to electrostatic repulsions, is insensitive to the presence of different ions. In PBS containing BSA (0.5 mg/ml), the \( D_h \) and polydispersity of Fe₃O₄@PEG-Ner-10 particles increased after 1 and 48 h to 137 and 200 nm and PI to 0.22 and 0.6, respectively (Fig. 4). Interestingly, the \( D_h \) and PI of both Fe₃O₄@PEG-Ner-20 and -31 particles did not change with time and the sizes were similar to those in neat PBS, confirming that the surface was well protected by PEG. Rapid increase of hydrodynamic Fe₃O₄@PEG-Ner-10 nanoparticle size with time was attributed to protein corona formation due to higher \( \zeta \)-potential.

Table 1. Characterization of the Fe₃O₄@PEG-Ner nanoparticles. \( D_h \) - number-average particle diameter (TEM); \( D_P \) - dispersity (TEM); \( D_h \) - hydrodynamic diameter (DLS); PI - polydispersity (DLS); \( \sigma^b \) - grafting density; \( \zeta \)-potential; \( M_s^c \) - saturation magnetization; \( M_r^c \) - remnant magnetization.

| Particles          | \( D_h \) (nm) | \( D_P \) (wt.%) | PI  | \( \zeta \)-potential (mV) | Coating* (wt.%) | \( \sigma^b \) (PEG/nm²) | \( M_s^c \) (Am²/kg) | \( M_r^c \) (Am²/kg) |
|--------------------|----------------|----------------|-----|--------------------------|----------------|--------------------------|----------------------|----------------------|
| Fe₃O₄@PEG-Ner-10   | 10             | 1.05           | 35  | 0.2                      | 28.5           | 0.99                     | 34                   | 0                    |
| Fe₃O₄@PEG-Ner-20   | 20             | 1.03           | 40  | 0.1                      | 17             | 1.02                     | 40                   | 0.2                  |
| Fe₃O₄@PEG-Ner-31   | 31             | 1.05           | 65  | 0.14                     | 9              | 0.76                     | 42                   | 7                    |

Figure 2. (a) ATR FTIR spectra of OA-coated Fe₃O₄ and Fe₃O₄@PEG-Ner-10-31 particles and (b) TGA of Fe₃O₄@PEG-Ner-10-31 nanoparticles.
Nevertheless, the magnetic properties of studied particles were comparable with those published elsewhere, where $M_s = 51$ and 39.7 Am$^2$/kg$^{12,27}$, and enabled their efficient and quick manipulation by an external magnetic field; moreover, they were satisfactory for application of the nanoparticles as a MRI contrast agent in vivo. The absence of remanent magnetization ($M_r$) in the 10 nm particles or the negligibly small $M_r$ of the 20 nm particles confirmed their superparamagnetic character. In contrast, the 31 nm nanoparticles were ferrimagnetic with $M_r = 7$ Am$^2$/kg (Table 1).

Figure 3. Time dependence of (a) hydrodynamic diameter $D_h$ and (b) $\zeta$-potential of nanoparticles in water and PBS (pH = 7.4).

Figure 4. Time dependence of hydrodynamic diameter $D_h$ and polydispersity $P_I$ of nanoparticles in PBS (pH = 7.4) in the presence of BSA (0.5 mg/ml).

Figure 5. Dependence of relaxivity $r_2$ of Fe$_3$O$_4$@PEG-Ner nanoparticles on temperature at 0.5 T.
MR relaxivity of Fe₃O₄@PEG-Ner particles. As expected, the relaxivity ($r_2$) of diluted Fe₃O₄@PEG-Ner-10–31 colloids measured in vitro at 0.5 T magnetic field decreased with increasing temperature ranging from 5–65 °C (Fig. 5). This behavior was not surprising in the so-called motional averaging regime of the...
Fe₃O₄@PEG-Ner nanoparticles exhibited the lowest relaxivity due to their smaller saturation magnetization. Relaxivities (reciprocal values of relaxation times related to Fe₃O₄ crystal unit) of the particles corresponded to already published results with respect to their size and used magnetic field. Some differences can be caused by different coatings.

Fe₃O₄@PEG-Ner nanoparticle biodistribution in mice assessed by MRI. With the aim to find an optimal size for a prolonged blood stream circulation, newly synthesized 10-, 20-, and 31-nm particles were tested in experimental animals. MRI confirmed the presence of the Fe₃O₄@PEG-Ner nanoparticles in the blood stream of the mice after intravenous injection, which was indicated by a hypointense signal in the vessels and tissues that are well-perfused by blood. The in vivo distribution of the nanoparticles depended on the particle size. As the nanoparticles were cleared from the blood stream through excretion by the hepatobiliary route, the hypointense signal was observed mainly in the liver tissue (Fig. 6). Interestingly, a strong hypointense signal in the liver shortly after administration (10 and 60 min) was observed for the Fe₃O₄@PEG-Ner-10 and -31 particles, whereas the Fe₃O₄@PEG-Ner-20 nanoparticles provided a weak signal, likely because their clearance was slower and the blood circulation time was longer. Four hours after administration, a strong hypointense signal in the liver was observed, even for Fe₃O₄@PEG-Ner-20 nanoparticles. It corresponded to typical final biodistribution of iron oxide nanoparticles (80–90% in liver, 5–8% in spleen, and 1–2% in bone marrow). It was reported, that clearance of magnetic nanoparticles from liver can be longer than 14 days. A noticeable hypointense signal was also observed in the kidneys due to high blood perfusion of this organ. However, certain entrapment of the nanoparticles in the kidney tissue could not be excluded.

Circulation of Fe₃O₄@PEG-Ner nanoparticles in blood. The concentration of the Fe₃O₄@PEG-Ner nanoparticles in the blood of experimental animals was determined by T₂ relaxometry measurements (Fig. 7). Notably, the reduction in Fe₃O₄ concentration (for all three particle sizes) in the blood did not follow an exponential course but was rather linear, which suggests that the elimination of the particles did not solely depend on their blood concentrations. Non-exponential elimination contradicts some already published data, which showed monoexponential decay of iron oxide concentration. However, these particles were coated with carboxydextran or poly(acrylic acid). Carboxydextran-coated particles have circulation half-time in the order of minutes, whereas the Fe₃O₄@PEG-Ner-20 nanoparticles provided a weak signal, likely because their clearance was slower and the blood circulation time was longer. Four hours after administration, a strong hypointense signal in the liver was observed, even for Fe₃O₄@PEG-Ner-20 nanoparticles. It corresponded to typical final biodistribution of iron oxide nanoparticles (80–90% in liver, 5–8% in spleen, and 1–2% in bone marrow). It was reported, that clearance of magnetic nanoparticles from liver can be longer than 14 days. A noticeable hypointense signal was also observed in the kidneys due to high blood perfusion of this organ. However, certain entrapment of the nanoparticles in the kidney tissue could not be excluded.

Generally, the circulation of nanoparticles in the blood is influenced by many factors. For example, it depends on retention in different organs, primarily the liver, which typically represents the main route of iron oxide elimination. The circulation time may also be related to the hydrodynamic diameter. Relatively long circulation times were found for Fe₃O₄@PEG-Ner-20 nanoparticles (14 h) compared to those of other particle sizes. Although the hydrodynamic size and density of the PEG chains grafted to the Fe₃O₄@PEG-Ner-10 and Fe₃O₄@PEG-Ner-20 particle surfaces were similar (Table 1), the former particles had a shorter circulation time, which could have
been due to their tendency to aggregate and a lower negative $\zeta$-potential in PBS, leading to increased opsonization and faster elimination from the blood stream. This observation is in agreement with an earlier report describing the interaction of $\beta$-2 glycoprotein and apolipoprotein B with negatively charged surfaces\textsuperscript{54}. Both of these liver proteins are able to attach to foreign substances and transport them \textit{in vivo} by the lymphatic system or blood\textsuperscript{55}. They also adhere to negatively charged nanoparticles, transferring them into the liver. Regarding the Fe\textsubscript{3}O\textsubscript{4}@PEG-Ner-31 nanoparticles, their PEG density was the lowest of the investigated samples, and the blood circulation time was short. Therefore, it can be speculated that the relatively high PEG density of Fe\textsubscript{3}O\textsubscript{4}@PEG-Ner-20 particles formed a more stable coating than that in Fe\textsubscript{3}O\textsubscript{4}@PEG-Ner-31 particles, which improved the separation of the core from the outer environment and led to slower elimination of the nanoparticles by the liver. Long circulation of the Fe\textsubscript{3}O\textsubscript{4}@PEG-Ner-20 nanoparticles was thus probably given by superior combination of PEG-neridronate coating and proper size of the particles. Moreover, protein corona (both soft and hard) formed on nanoparticles in the blood stream can strongly affect their behavior in biological systems, in particular, interaction with platelets and blood cells, which in turn influences removal of the particles from blood\textsuperscript{56}. Although the fast elimination of the contrast agent is typically desirable in clinical practice to minimize possible adverse effects, prolonged particle circulation might be advantageous for imaging organs or structures requiring longer exposure for the entrapment of the contrast agent.

**MRI of Fe\textsubscript{3}O\textsubscript{4}@PEG-Ner nanoparticles in tumor bearing mice.** Finally, the Fe\textsubscript{3}O\textsubscript{4}@PEG-Ner-20 nanoparticles with the longest blood circulation time were intravenously injected into mice with an induced subcutaneous tumor, and MRI scans were obtained (Fig. 8). A hypointense signal was observed in the liver 4 h
after particle administration, whereas the signal decrease in the tumor was insignificant. The particles were then administered repeatedly after 24 and 48 h to prolong the blood circulation time and enable retention of the particles by the enhanced permeability and retention (EPR) effect. Although a small but significant signal decrease was observed in the tumor shortly after the second and third administrations (Fig. 9), the nanoparticles were quickly eliminated. No signal change was detected compared to the precontrast examination three days after the injection of the final dose, which indicated low retention of the nanoparticles in the tumor.

Cleary, the EPR effect was not observed in our study, which is in agreement with clinical practice, where tumor targeting via EPR has not been proved in humans57. This is the reason why intratumoral injections are generally preferred to achieve an accumulation of the particles in a tumor. In addition, the internalization of PEG-coated particles in the cells may be hindered by the nonionogenic nature of PEG and its steric repulsions and antifouling properties58. Moreover, biological applications of PEG-modified particles were recently questioned due to enhanced serum protein binding and a significant reduction in drug delivery59. Other studies have also reported on the immunogenicity of PEG60, which requires the development of innovative coatings and/or targeting moieties for blood delivery systems in the near future.

Conclusion
Magnetite nanoparticles with a controlled size and uniform size distribution were prepared by thermal decomposition of Fe(III) oleate and mandelate in nonpolar high-boiling point solvents. According to TEM, the Fe3O4 size was 10, 20, and 31 nm, with dispersity D = 1.05, 1.03, and 1.05, respectively, indicating a very narrow particle size distribution. In the literature, such particle sizes were not yet investigated in terms of their biodistribution in an animal. Particle size uniformity is important in biomedical applications, which require high quality particles with identical physical, chemical, and biological properties to achieve reproducibility of the results. The Fe3O4 surface was hydrophilized with PEG-containing bisphosphonate anchoring groups to prevent particle aggregation. In contrast to commonly used PEG-alendronate, the particles were modified by novel PEG-neridronate, which rendered them with superior colloidal stability in physiological media. According to the thermogravimetric analysis, the amount of the particle coating decreased with increasing particle size, which was attributed to the different surface-to-volume ratios of the particles. The calculations showed that the 10, 20, and 31 nm particles were coated with brush-like PEG shells with grafting densities of 0.99, 1.02, and 0.76 PEG/nm², respectively. The DS of the Fe3O4 particles ranged from 34 to 62 nm in PBS (pH 7.4), which is ideal for biomedical applications41. In addition, the DS was nearly constant in water and PBS for one week, confirming the superior colloidal stability of the particles that was maintained by the steric repulsion of PEG. The particle relaxivity increased with increasing size. Fe3O4 clearance from the blood stream in the mouse model exhibited a linear time dependence, which was attributed to the uniform particle size that provided the same properties. The particle circulation time was attributed to the Fe3O4 size and the quality of the surface coating. The in vivo elimination of the Fe3O4 particles depended on the PEG density on the particle surface and the ζ-potential rather than the particle size. Because the PEG density was high on the Fe3O4@PEG-Ner-20 particles, they circulated in the blood for the longest period of time out of all the investigated samples.

In a mouse tumor model, the majority of the Fe3O4@PEG-Ner-20 nanoparticles were taken up by the liver after intravenous injection. Significant retention of the particles in the tumor was not achieved, even with repeated administration. Therefore, alternative strategies for PEG-modified particles must be investigated to prolong blood circulation times and/or to achieve specific targeting in a tumor.

References
1. Ramos, A. P., Cruz, M. A. E., Tovani, C. B. & Ciancaglini, P. Biomedical applications of nanotechnology. Biophys. Rev. 9, 79–89 (2017).
2. Sarmento B., Neves J. D. (Eds), Biomedical Applications of Functionalized Nanomaterials: Concepts, Development and Clinical Translation (1st Ed.), Elsevier, Oxford, United Kingdom (2018).
3. Estelrich, J., Sánchez-Martín, M. J. & Busquets, M. A. Nanoparticles in magnetic resonance imaging: From simple to dual contrast agents. Int. J. Nanomed. 10, 1727–1741 (2015).
4. Xiong, E., Huang, S. & Gu, N. Magnetic nanoparticles: Recent developments in drug delivery system. Drug. Dev. Ind. Pharm. 44, 697–706 (2018).
5. Guibert, C., Dupuis, V., Peyre, V. & Fresnais, J. Hyperthermia of magnetic nanoparticles: Experimental study of the role of aggregation. J. Phys. Chem. C 119, 28148–28154 (2015).
6. Numara, K. M. & Tofail, S. A. M. Nanosystems: The use of nanowalls, metallic, bimetallic, and magnetic nanoparticles in biomedical applications. Phys. Chem. Chem. Phys. 17, 27981–27995 (2015).
7. Liu, G., Gao, J., Ai, H. & Chen, X. Applications and potential toxicity of magnetic iron oxide nanoparticles. Small 9, 1533–1545 (2013).
8. Wu, M. & Huang, S. Magnetic nanoparticles in cancer diagnosis, drug delivery and treatment. Mol. Clin. Oncol. 7, 738–746 (2017).
9. Gupta, A. K., Naregalkar, R. R., Vaidya, V. D. & Gupta, M. Recent advances on surface engineering of magnetic iron oxide nanoparticles and their biomedical applications. Nanomedicine 2, 23–39 (2007).
10. Liang, G., Han, J. & Hao, Q. Gram-scale preparation of iron oxide nanoparticles with renal clearance properties for enhanced T1-weighted magnetic resonance imaging. ACS Appl. Bio Mater. 1, 1389–1397 (2018).
11. Leal, M. P. et al. Long-circulating PEGylated manganese ferrite nanoparticles for MRI-based molecular imaging. Nanoscale 7, 2050–2059 (2015).
12. Feng, Q. et al. Uptake, distribution, clearance, and toxicity of iron oxide nanoparticles with different sizes and coatings. Sci. Rep. 8, 2082 (2018).
13. Gu, L., Fang, R. H., Sailor, M. J. & Park, J. H. In vivo clearance and toxicity of monodisperse iron oxide nanocrystals. ACS Nano 6, 4947–4954 (2012).
14. Kolosnjaj-Tabi, J. et al. Biotransformations of magnetic nanoparticles in the body. Nano Today 11, 280–284 (2016).
15. Wu, W., He, Q. & Jiang, C. Magnetic iron oxide nanoparticles: Synthesis and surface functionalization strategies. Nanoscale Res. Lett. 3, 397–415 (2008).
16. Hufschmid, R. et al. Synthesis of phase-pure and monodisperse iron oxide nanoparticles by thermal decomposition. Nanoscale 7, 11142–11154 (2015).
17. Hasany, S. F., Ahmed, I., Rajan, J. & Rehman, A. Systematic review of the preparation techniques of iron oxide magnetic nanoparticles. J. Nanosci. Nanotechnol. 2, 148–158 (2012).
18. Mosqueira, V. C. et al. Biodistribution of long-circulating PEG-grafted nanocapsules in mice: Effects of PEG chain length and density. Pharm. Res. 18, 1411–1419 (2001).
19. Gref, R. et al. ‘Stealth’ corona-core nanoparticles surface modified by polyethylene glycol (PEG): Influences of the corona (PEG chain length and surface density) and of the core composition on phagocytic uptake and plasma protein adsorption. Colloids Surf. B 18, 301–313 (2000).
20. Guénié, E., Hardouin, J., Lalatonne, Y. & Motte, L. Bivalent alkyne-bisphosphate as clickable and solid anchor to elaborate multifunctional iron oxide nanoparticles with microwave enhancement. J. Nanoparticle Res. 14, 965 (2012).
21. Zhang, Q. et al. Synthesis of well-defined catechol polymers for surface functionalization of magnetic nanoparticles. Polym. Chem. 7, 7002–7010 (2016).
22. Barrow, M., Taylor, A., Murray, P., Rosseinsky, M. J. & Adams, D. J. Design considerations for the synthesis of polymer coated iron oxide nanoparticles for stem cell labelling and tracking using MRI. Chem. Soc. Rev. 44, 6733–6748 (2015).
23. Patsula, V., Petrovský, E., Kovářová, J., Konefal, R. & Horák, D. Monodisperse superparamagnetic nanoparticles by thermolysis of Fe(III) oleate and mandelate complexes. Colloid. Polym. Sci. 292, 2097–2110 (2014).
24. Zheng, J. et al. Anchoring group effects of surface ligands on magnetic properties of Fe3O4 nanoparticles: Towards high performance MRI contrast agents. Adv. Mater. 26, 2694–2698 (2014).
25. Lalatonne, Y. et al. Bis-phosphonates-ultra small superparamagnetic iron oxide nanoparticles: A platform towards diagnosis and therapy. Chem. Commun. 22, 2553–2555 (2008).
26. Kostiv, U. et al. A simple neridronate-based surface coating strategy for upconversion nanoparticles: Highly colloidal stable 111-iodolabeled NaYF4:Yb3+/Er3+@PEG nanoparticles for multimodal in vivo tissue imaging. Nanoscale 9, 16680 (2017).
27. Sandford, L. et al. Bisphosphonate-anchored PEGylation and radiolabeling of superparamagnetic iron oxide: Long-circulating nanoparticles for in vivo multimodal (T1 MRI-SPECT) imaging. ACS Nano 7, 500–512 (2013).
28. Zhang-Yu, Y. et al. Alendronate as a robust anchor for ceria nanoparticle surface coating: Facile binding and improved biological properties. RSC Adv. 4, 59965–59969 (2014).
29. Kachbi-Rhâfîlah, S. et al. Towards potential nanoparticle contrast agents: Synthesis of new functionalized PEG bisphosphonates. Helv. Chim. Acta 13, 1366–1371 (2016).
30. Khandhar, A. P. et al. Evaluation of PEG-coated iron oxide nanoparticles as blood pool tracers for preclinical magnetic particle imaging. Nanoscale 9, 1299–1306 (2017).
31. Nosrati, H. et al. New insight about biocompatibility and biodegradability of iron oxide magnetic nanoparticles: Stereological and in vivo MRI monitor. Sci. Rep. 9, 7173 (2019).
32. Peng, B. et al. Synthesis of Fe3O4/APTES/PEG diacid functionalized magnetic nanoparticles for MR imaging. Colloids Surf. A 328, 52–59 (2008).
33. Xie, J. et al. Controlled PEGylation of monodisperse Fe3O4 nanoparticles for reduced non-specific uptake by macrophage cells. Adv. Mater. 19, 3163–3166 (2007).
34. Mejias, R. et al. Liver and brain imaging through dimercapsusuccinic acid-coated iron oxide nanoparticles. Nanomedicine 5, 397–408 (2010).
35. Park, J. et al. Ultra-large-scale synthesis of monodisperse nanocrystals. Nat. Mater. 3, 891–895 (2004).
36. D’souza, A. A. & Shegokar, R. Polyeethylene glycol (PEG): A versatile polymer for pharmaceutical applications, Expert Opin. Drug Del. 13, 1257–1275 (2016).
37. Corrado, A., Colia, R. & Cantatore, F. P. Neridronate: From experimental data to clinical use. Clin. Med. Insights Ther. 9, 1–8 (2017).
38. Labouta, H. I. et al. Surface-grafted polyeethylene glycol conformation impacts the transport of PEG-functionalized liposomes through a tumour extracellular matrix model. RSC Adv. 8, 7697–7708 (2018).
39. Rahme, K. et al. PEGylated gold nanoparticles: Polymer quantification as a function of PEG lengths and nanoparticle dimensions. RSC Adv. 3, 6085–6094 (2013).
40. Perry, J. L. et al. PEGylated PRINT nanoparticles: The impact of PEG density on protein binding, macrophage association, biodistribution, and pharmacokinetics. Nano Lett. 12, 5304–5310 (2012).
41. Cornell, R. M. & Schwertmann, U. The iron Oxides: Structure, Properties, Reactions. Occurrences and Uses. (Wiley, Weinheim, 2003).
42. Zhou, Z. et al. Anisotroped shaped iron oxide nanostructures: Controlled synthesis and proton relaxation shortening effects. Chem. Mater. 27, 3505–3515 (2015).
43. Issa, B., Olbaid, I. M., Albiss, B. A. & Haik, Y. Magnetic nanoparticles: Surface effects and properties related to biomedical applications. Int. J. Mol. Sci. 14, 21266–21305 (2013).
44. Morales, M. P., Veintemillas-Verdaguer, S., Montero, M. I. & Serna, C. J. Surface and internal spin canting in γ-Fe2O3 nanoparticles. Chem. Mater. 11, 3058–3064 (1999).
45. Huang, C. C. et al. Size-control synthesis of structure deficient truncated octahedral Fe3O4 nanoparticles: High magnetization magnetites as effective hepatic contrast agents. J. Mater. Chem. 21, 7472–7479 (2011).
46. Gillis, P., Moisy, F. & Brooks, R. A. On T2-shortening by strongly magnetized spheres: A partial refocusing model. Magn. Reson. Med. 47, 257–263 (2002).
47. Kaman, O. et al. Transverse relaxivity of nanoparticle contrast agents for MRI: Different magnetic cores and coatings. IEEE Trans. Magn. 54, 5300405 (2018).
48. Rohrer, M., Bauer, H., Mintorovitch, J., Requardt, M. & Weimann, H. J. Comparison of magnetic properties of MRI contrast media solutions at different magnetic field strengths. Invest. Radiol. 46, 221–224 (2011).
49. Koohi, E., Lohrke, J., Ide, A., Schütz, G. & Dassler, K. Studying the effect of particle size and coating type on the blood kinetics of superparamagnetic iron oxide nanoparticles. Int. J. Nanomed. 7, 4447–4458 (2012).
50. Kojima, C. et al. Dendrimer-based MRI contrast agents: The effects of PEGylation on relaxivity and pharmacokinetics. Nanomedicine 7, 1001–1008 (2011).
51. Ashraf, S. et al. In vivo fate of free and encapsulated iron oxide nanoparticles after injection of labelled stem cells. Nanoscale Adv. 1, 367–377 (2019).
52. Urbano-Bojorge, A. L. et al. Comparison of magnetometry and relaxometry measures of magnetic nanoparticles deposited in biological samples. J. Nano. Res.-SW 31, 129–137 (2015).
53. Allen, T. M., Hansen, C., Martin, F., Redemann, C. & Yau-Young, A. Liposomes containing synthetic lipid derivatives of polyethylene glycol (PEG) show prolonged circulation half-lives in vivo. Biochem. Biophys. Acta 1066, 29–36 (1991).
54. Simberg, D. et al. Differential proteomics analysis of the surface heterogeneity of dextran iron oxide nanoparticles and the implications for their in vivo clearance. Biomaterials 30, 3926–3933 (2009).
55. Arvizo, R. R. et al. Modulating pharmacokinetics, tumor uptake and biodistribution by engineered nanoparticles. PLoS One 6, e24374 (2011).
56. Bertrand, N. et al. Mechanistic understanding of in vivo protein corona formation on polymeric nanoparticles and impact on pharmacokinetics. Nat. Commun. 8, 777 (2017).
57. Danhier, F. To exploit the tumor microenvironment: Since the EPR effect fails in the clinic, what is the future of nanomedicine? J. Control. Release 244, 108–121 (2016).
58. Ekblad, T. et al. Poly(ethylene glycol)-containing hydrogel surfaces for antifouling applications in marine and freshwater environments. Biomacromolecules 9, 2775–2783 (2008).
59. Verhoef, J. J. & Anchordoquy, T. J. Questioning the use of PEGylation for drug delivery. Drug Deliv. Transl. Res. 3, 499–503 (2013).
60. Lila, A. S. A., Kiwada, H. & Ishida, T. The accelerated blood clearance (ABC) phenomenon: Clinical challenge and approaches to manage. J. Control. Release 172, 38–47 (2013).
61. Arami, H., Khandhar, A., Liggitt, D. & Krishnan, K. M. In vivo delivery, pharmacokinetics, biodistribution and toxicity of iron oxide nanoparticles. Chem. Soc. Rev. 44, 8576–8607 (2015).

Acknowledgements
This research was supported by the Czech Science Foundation (No. 17-04918S), NPU II (LQ1604) provided by MEYS and CZ.1.05/1.1.00/02.0109 BIOCEV provided by ERDF and MEYS. J.K. thanks also to the Czech Science Foundation (No. 18-07983S). The in vivo experiments were supported by the institutional grants by the Ministry of Education, Youth and Sports of the Czech Republic (LM2015062 Czech-BioImaging and SVV 260371/2018).

Author Contributions
V.P. synthesized the particles, D.H. wrote the manuscript, J.K. intravenously applied the particles in mice, H.M. was involved in characterization of the particles, V.L. synthetized PEG-neridronate, P.F. performed MRI, V.H. was involved in relaxivity measurements, T.H. collected the blood samples, P.P. cultivated the tumor cells, and L.Š. coordinated the biological experiments.

Additional Information
Competing Interests: The authors declare no competing interests.

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2019